Amgen agreed to acquire Dark Blue Therapeutics and its discovery platform for targeted degradation, including lead candidate DBT‑3757, in a transaction valued at $840 million. Dark Blue’s MLLT1/MLLT3‑targeting program demonstrated preclinical activity in AML and ALL, offering Amgen an entry into a novel small‑molecule degrader modality for hematologic malignancies. Amgen cited the acquisition as complementary to its oncology research agenda and targeted protein degradation strategy. The deal brings discovery know‑how and a candidate that could enter clinical development under Amgen’s R&D engine, accelerating translation and global development plans. The transaction reflects big‑pharma appetite for early‑stage platforms that produce mechanistically distinct candidates, particularly in hematologic oncology where new target classes and modalities remain high priority.